Latest News
- July 09, 2025Global Recognition! International Publication of Phase I Hepatology Clinical Trial
- July 03, 2025Successful completion of an unannounced USFDA inspection
- June 30, 2025Successful completion of 2 USFDA inspections with ZERO 483 in June 2025
- June 24, 2025Two USFDA inspections in ophthalmology, with ZERO 483
- June 17, 2025CBCC Brings the Community Together at BIO 2025!
January 07, 2024
We welcome Dr David Bearss to our strategic advisory board
We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.
Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.
We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
